The incidence of hepatocellular carcinoma (HCC) in the United States is increasing, but the clinical characteristics of American patients with HCC have not been well described. The aims of this study were to determine the etiology of liver disease and short-term outcome among HCC patients presenting to a single center in the United States. One hundred five consecutive patients with HCC were studied; mean age was 59 years, 67% were men, and 76% were non-Hispanic white. The most common etiology of liver disease was hepatitis C (51%) and cryptogenic cirrhosis (29%). Half of the patients with cryptogenic cirrhosis had histologic or clinical features associated with nonalcoholic fatty liver disease (NAFLD).
been increasing over the last decade.2 In 1998, intrahepatic liver cancer ranked as the 6th most common malignancy in the United States, resulting in a death rate of 3.5 per 100,000.' Much of the increase in intrahepatic liver cancer is related to an increase in the incidence of HCC. The increase in incidence of HCC in the United States has been attributed to the hepatitis C virus (HCV) epidemic, but data on the prevalence of HCV infection among patients with HCC in the United States are not available. Recently, nonalcoholic fatty liver disease (NAFLD) has been recognized to be one of the most common causes of chronic liver disease in the United States.3 Several studies have demonstrated that NAFLD may progress to cirrhosis. [4] [5] [6] In addition, recent studies found that a high percentage of patients who underwent liver transplantation for cryptogenic cirrhosis probably had NAFLD, indicating that NAFLD may be an important cause of end-stage liver di~ease.7.~ A study from Italy also reported an association between NAFLD and HCC.IO Survival of patients with HCC has improved minimally over the last 2 decades, with I-year survival rate 1349 increasing from 14% in 1977 to 1981 to 23% in 1992 to 1996, whereas the 5-year survival rate rose from 2% to 5%. These disappointing results were observed despite dramatic improvements in the survival of patients with other malignancies such as breast or colon cancer during the same time period. Several prospective studies have found that surveillance of high-risk individuals can increase the rate of detection of early HCC. ' States is detected by surveillance.
The aims of this prospective study were to determine the etiology of liver disease and tumor staging at diagnosis among HCC patients presenting to a single referral center in the United States. In addition, we determined whether patients whose tumor was detected via surveillance were more likely to be candidates for surgical therapy than patients presenting with clinical symptoms. The results in our cohort of 105 consecutive HCC patients form the basis of this report.
Patients and Methods
Patients andEtioZogy. A database of all patients with a diagnosis of HCC was established in January, 2000, at the University of Michigan Medical Center per local Institutional Review Board guidelines. Written informed consent was obtained from each patient. The diagnostic criteria of HCC was based on liver histology, and, in the absence of histology, an AFP >200 ng/mL with a hypervascular mass on triple-phase computerized tomography (CT) scan or magnetic resonance imaging (MRI). The age at diagnosis, gcnder, ethnicity, body mass index (BMI), estimated duration from diagnosis of liver disease to diagnosis of HCC, Child-Turcotte-Pugh (CTP) score, serum a-fetoprotein (AFP), and tumor size and location were recorded.
Etiology of underlying liver disease was attributed to H C V based on detection of hepatitis C antibody/HCV RNA in serum, hepatitis B (HBV) [ (12) 5 (5) 3 (3) 4 (4) 41 (39) 30 (29) 13 (12) 11 (10) 6 (6) 4 (4) 2. cirrhosis. There was no significant difference in gender, tumor size, and percentage with HCC surveillance between these 2 groups. Patients with cryptogenic cirrhosis as the underlying liver disease were less likely to have undergone HCC surveillance (23% vs. 61%, P = .01). This resulted in larger tumors at diagnosis (7.6 vs. 4.4 cm, P = .03), and a lower proportion of patients eligible for surgical (3 underwent resection, 1 placed on transplant waiting list) or local ablation therapy (5 had radio fre- 
Discussion
In this case series of 105 consecutive patients with HCC presenting to a tertiary center in the United States, we confirmed that H C V is the most common underlying liver disease. Nevertheless, HCV only accounted for 51% of our cases, with cryptogenic liver disease accounting for quency ablation). During follow-up, 1 1 (37%) patients with cryptogenic liver disease died. There was no difference in age, gender, ethnicity, and
Child class between group I and I1 patients ( Fifty percent of our patients had their tumors detected during surveillance. Patients who underwent surveillance had smaller tumors at diagnosis and were more likely to be eligible for surgical or local ablative therapies. In addition, there was a significant improvement in survival among those who underwent tumor surveillance. Our data support previous findings that surveillance of patients with cirrhosis using AFP and ultrasound can lead to early diagnosis of HCC.'3-'5,25 We recognize that the 2 groups of patients were not randomized, and improved survival in group I patients may be related to lead-time bias. Nevertheless, our data corroborate previous studies indicating that surveillance may increase the rate of early detection and eligibility for curative therapies, which may in turn translate into improved survival.
Although the patients who underwent surveillance had smaller tumors, half of them had more than I tumor, and a third had portal vein invasion at diagnosis. The high proportion of patients with advanced tumors despite surveillance may be related to the heterogeneity in frequency of surveillance (every 6-12 months) performed by a diverse group of hepatologists. Even though HCC surveillance is usually performed at 6-month intervals, prior prospective studies have used varying intervals from 6 to 12 months. 26 We have recently implemented a stricter HCC surveillance program to determine whether we can improve our early detection rate. O u t disappointing results with surveillance may also be related to the insensitivity ofAFP in the early detection of HCC. Thus, 42% of group I patients had normal AFP levels at diagnosis, and only 19% had AFP levels >200 ng/mL. Because accuracy of ultrasound is dependent on operator skill and experience,27 more sensitive serum markers for HCC are needed to improve the results of HCC surveillance programs.
Preliminary results of an ongoing study in our center found that des-y carboxy prothrombin is a more sensitive marker in the detection of HCC than AFP.2x
In summary, we have reported the first large case series of HCC patients in the United States. W e found that, in addition to HCV, NAFLD is a common underlying liver disease in American patients with HCC. Prospective studies in patients with NASH will help determine the true incidence of HCC in this population. Because of the increasing prevalence of NAFLD, the incidence of HCC in the United States may continue to increase even after the consequences of the H C V epidemic have leveled off. Patients who underwent surveillance had smaller tumors at diagnosis and were more likely to be candidates for surgical or local ablative therapies. Although the 2 groups of patients in our series were not randomized, our findings suggest that surveillance of patients with cirrhosis can detect HCC at an earlier stage, possibly leading to an improved survival. Because of the low sensitivity of AFP, more reliable serum markers for HCC are needed to improve the results of surveillance programs.
